EL SEGUNDO, Calif. (AP) — Despite dealing with his share of injuries and learning a new offense, Justin Herbert is on one of the NFL's longest streaks without throwing an interception. Herbert enters the Los Angeles Chargers' game against the Tampa Bay Buccaneers on Sunday having thrown 335 passes without a pick. That's the fifth-longest run in league history. Aaron Rodgers holds the record of 402 for Green Bay in 2018. “It’s one of those things where you go play quarterback and you’re not worried about it. If I throw an interception, it is what it is,” Herbert said. “I’m doing everything I can to take care of the ball and make sure that I’m not putting the team in harm’s way. At the end of the day, you got to be aggressive downfield and you got to take your shots.” Herbert suffered a sprained left ankle and bruised left leg in last Sunday's 19-17 loss at Kansas City . He practiced Thursday after sitting out Wednesday. Herbert — whose last interception came midway through the first quarter on Sept. 15 at Carolina — has also joined Tom Brady as the only players who have not thrown an interception in 11 straight games with a minimum of 15 attempts in each. Brady accomplished the feat with New England in 2010. “It's pretty amazing. I said to him the other day, ‘Thank you for not having us overcome some interceptions.’ It's huge and has kept us in a lot of games,” offensive coordinator Greg Roman said. “You have a smart quarterback that is trying to win the game. He's not trying to win stats and understands the importance of taking care of the football.” Herbert will face a Tampa Bay defense that has only six interceptions, tied for sixth fewest in the league. “He does a great job taking care of the football and understanding the offense," Tampa Bay coach Todd Bowles said. “If it’s not there, he can use his legs; if it’s there, he’s got a cannon of an arm. He can zip it in. He trusts his receivers — they do a good job of mixing it up.” The Chargers (8-5) have dropped two of their past three, but hold the second wild card spot in the AFC. The Bucs (7-6) have won three straight since their Week 11 bye, which gave them a chance to regroup following a stretch in which they lost five of six. All of the victories, which have carried them back to the top of the NFC South, have come against last-place teams (Giants, Panthers, Raiders). Tampa Bay’s Baker Mayfield has already matched a career high with 28 touchdown passes, but he hasn’t done as good a job of protecting the ball as he did a year ago. He’s thrown more interceptions through 13 games (13) than he did in 17 games (10) a year ago. He threw for 295 yards and three TDs during last week’s 28-13 win over Las Vegas , yet also turned the ball over three times to help the Raiders keep it close until the fourth quarter. “We have to understand, especially when we’re in the red zone and we’re in the scoring territory, we can’t turn it over. That’s No. 1,” Bowles said. “You don’t like the turnovers, period. Every now and then they can happen, but we have to do a better job taking care of the football as an offensive staff, period,” Bowles added. “Between the coaches and the players, we need to do a better job of focusing on exactly what we want to get done, how we need to get it done, and make sure we execute it every play. It’s not just on Baker, it’s on everybody.” Los Angeles leads the league in scoring defense, allowing 15.9 points per game. It is also fifth in sacks (39) and three-and-out percentage (24.3%) and seventh in third-down defense. “They’re really gap sound,” Mayfield said. “They don’t get bad eyes down there. Everybody does their part in whatever the play's called. Nobody tries to do too much and then like I said earlier, they fly to the ball. They don’t let you get explosives. Obviously, in the red zone, they’re closing windows pretty quick.” The Bucs are 7-1 in December and January regular-season games dating to last season and 19-5 in those games going back to 2020. The Chargers are the only opponent with a winning record that Tampa Bay will face over the final seven weeks of the season. Tampa Bay's running backs catching the ball out of the backfield. The Bucs are second in the league in receptions by running backs (85), first in receiving yards (726) and tied for the league lead with six touchdowns. Rachaad White is fourth among backs in yards after the catch with 420. He has 41 catches, and Bucky Irving has 36. “They're similar in the sense they can do the same things but different in style. They're both really shifty,” Chargers defensive coordinator Jesse Minter said. “The goal of offense is to get the ball to people in space with angles on blockers. They do a good of that.” AP Sports Writer Fred Goodall in Tampa, Florida, contributed to this report. AP NFL: https://apnews.com/hub/nfl
Barclays PLC increased its stake in Wave Life Sciences Ltd. ( NASDAQ:WVE – Free Report ) by 171.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 159,241 shares of the company’s stock after buying an additional 100,498 shares during the quarter. Barclays PLC owned about 0.13% of Wave Life Sciences worth $1,307,000 as of its most recent SEC filing. A number of other large investors have also recently made changes to their positions in WVE. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Wave Life Sciences by 23.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company’s stock valued at $37,000 after acquiring an additional 856 shares during the period. Profund Advisors LLC bought a new stake in shares of Wave Life Sciences during the second quarter worth $53,000. Principal Financial Group Inc. purchased a new stake in shares of Wave Life Sciences during the second quarter valued at $74,000. Mackenzie Financial Corp grew its holdings in shares of Wave Life Sciences by 13.6% in the second quarter. Mackenzie Financial Corp now owns 15,887 shares of the company’s stock worth $79,000 after purchasing an additional 1,905 shares during the last quarter. Finally, Point72 DIFC Ltd purchased a new position in Wave Life Sciences in the 3rd quarter worth about $98,000. 89.73% of the stock is owned by hedge funds and other institutional investors. Insider Activity In other Wave Life Sciences news, CEO Paul Bolno sold 90,474 shares of the company’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $15.00, for a total value of $1,357,110.00. Following the completion of the transaction, the chief executive officer now owns 268,585 shares in the company, valued at approximately $4,028,775. This represents a 25.20 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link . Also, insider Chris Francis sold 36,000 shares of Wave Life Sciences stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $576,000.00. The disclosure for this sale can be found here . Insiders sold a total of 436,544 shares of company stock valued at $6,271,569 in the last quarter. 29.10% of the stock is currently owned by company insiders. Wave Life Sciences Trading Down 4.3 % Analyst Upgrades and Downgrades WVE has been the subject of a number of research analyst reports. Wells Fargo & Company lifted their target price on Wave Life Sciences from $11.00 to $22.00 and gave the company an “overweight” rating in a research report on Wednesday, October 16th. Leerink Partners lifted their price objective on Wave Life Sciences from $20.00 to $22.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of Wave Life Sciences in a report on Wednesday, November 13th. Royal Bank of Canada raised their target price on shares of Wave Life Sciences from $7.00 to $15.00 and gave the company a “sector perform” rating in a research report on Monday, October 21st. Finally, Truist Financial upped their price target on shares of Wave Life Sciences from $17.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, November 12th. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $22.22. Read Our Latest Report on Wave Life Sciences About Wave Life Sciences ( Free Report ) Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Featured Stories Five stocks we like better than Wave Life Sciences Best Stocks Under $5.00 Buffett Takes the Bait; Berkshire Buys More Oxy in December Why Invest in 5G? How to Invest in 5G Stocks Top 3 ETFs to Hedge Against Inflation in 2025 TSX Venture Exchange (Formerly Canadian Venture Exchange) These 3 Chip Stock Kings Are Still Buys for 2025 Want to see what other hedge funds are holding WVE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Wave Life Sciences Ltd. ( NASDAQ:WVE – Free Report ). Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter .Lara Trump stepping down as RNC co-chair and addressing speculation about Florida Senate seatSuspect in UnitedHealthcare CEO killing charged with murder in New York, court records show
Phillies gamble on 1-year contract for 2-time All-Star closer Jordan Romano
Azerbaijan Airlines Crash: What To Know As U.S. Official Suggests Russia Struck Down Flight
SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of persons and entities that purchased or otherwise acquired ASP Isotopes Inc. (NASDAQ: ASPI) securities between October 30, 2024 and November 26, 2024. ASP Isotopes is a development stage advanced materials company focused on the production, enrichment, and sale of isotopes. For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that ASP Isotopes Inc. (ASPI) Misled Investors Regarding its Uranium Enrichment Technology and Facility According to the complaint, during the class period, defendants failed to disclose that the Company: (1) overstated the potential effectiveness of its enrichment technology; (2) overstated the development potential of its high assay low-enriched uranium facility; and (3) overstated the Company’s nuclear fuels operating segment results. Plaintiff alleges that on November 26, 2024, market research firm Fuzzy Panda Research published a report that alleged the Company is “using old, disregarded laser enrichment technology to masquerade as a new, cutting-edge Uranium enrichment.” The report revealed a series of experts interviewed stated the Company’s reported cost estimates and timeline for building its HALEU uranium facilities was misleading to the point of being “delusional.” The report further alleged the Company had significantly overstated the significance of its agreement with TerraPower, which was only a “non-binding” memorandum of understanding entered into to “put pressure on [TerraPower’s] real suppliers.” The report quoted a former TerraPower executives as stating that ASP Isotopes was “missing the manufacturing; They are missing the processes as well; They still have to develop the HALEU...the most important part.” On this news, the Company’s stock price fell $1.80 or 23.53%, to close at $5.85 per share on November 26, 2024, and continued to fall on the subsequent trading date, falling $0.83 or 14.19%, to close at $5.02 per share on November 27, 2024. What Now: You may be eligible to participate in the class action against ASP Isotopes Inc. Shareholders who want to serve as lead plaintiff for the class must submit their application to the court by February 3, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here . All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders. To be notified if a class action against ASP Isotopes Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/af960bd5-1ae2-4ed3-afe3-591b09ab920bAlabama 5-Star signee Keelon Russell reveals teams tried to flip him with NIL offers
Anita AI: The First AI-Driven Influencer Launches Her Own Token $ANITASouthern California representative Adam Schiff received a new job title on Monday. U.S. Senator.